KRAS and neoplasm: Furthermore, KRAS-G12V-specific TCR-engineered CD4+ T cells have shown excellent anti-tumor effectiveness in vitro and in xenograft models, identifying the neoantigens derived from HLA-DPB1*03:01 and DPB1*14:01.